# Efficacy and Safety of Hepatitis B Vaccine in Chronic Kidney Disease Patients

Study · id `cardio:ct-nct01933412` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01933412](<https://clinicaltrials.gov/study/NCT01933412>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01933412

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT01933412. Randomized; no masking; primary purpose prevention. Start 2012-03 (registry gives no type); primary completion 2013-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT01933412, source copy `cardio:ctgov-nct01933412-2013-09-02`, retrieved 2026-10-26)
- Start date: 2012-03 (registry gives no type) (ClinicalTrials.gov record NCT01933412, source copy `cardio:ctgov-nct01933412-2013-09-02`, retrieved 2026-10-26)
- Primary completion: 2013-08 (anticipated) (ClinicalTrials.gov record NCT01933412, source copy `cardio:ctgov-nct01933412-2013-09-02`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: Israel (ClinicalTrials.gov record NCT01933412, source copy `cardio:ctgov-nct01933412-2013-09-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01933412-2013-09-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Hepatitis B Vaccine in Chronic Kidney Disease Patients
- Condition: Chronic Kidney Disease
- Condition: Hepatitis B
- Intervention (Biological): Sci-B-Vac Hepatitis B Vaccine
- Intervention (Biological): Engerix B Hepatitis B Vaccine
- Lead sponsor: Tel-Aviv Sourasky Medical Center
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Tel-Aviv Sourasky Medical Center (`cardio:org-tel-aviv-sourasky-medical-center`)

## Provenance

Content hash: 6c7d709a73852e894869f960106e7cc70164516e6a63b981fb23f262d78640d6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
